Seth Laboratory

Exploring the mechanisms of liver injury and identify potential biomarkers for prevention, diagnosis and therapy.

The Seth Lab leads an international GenomALC Consortium, a global effort uncovering how our genes influence liver disease. By using advanced “multi‑omics” technologies – which analyse thousands of biological signals at once – the team has discovered new biomarkers and identified key clinical and genetic risk factors for conditions such as alcohol‑related liver disease (ALD) and metabolic dysfunction associated steatotic liver disease (MASLD).

The Lab has developed two major genetic tools now ready for clinical trials:

  • A Genetic Risk Score (GRS) that can identify people at high risk of ALD long before symptoms appear.
  • A Polygenic Risk Score (PRS) that predicts risk for both ALD and MASLD.

These personalised risk tools could transform liver care for the first time in this disease, by enabling detection of high-risk individuals, allowing early intervention for preventing progression to cirrhosis and hepatocellular carcinoma. Their impact extends beyond ALD to people with alcohol use disorders (AUD) and sub-clinical ALD, offering a new way to guide prevention and treatment.

In a clear example of bench to bedside, Seth Lab established Australia’s only clinical testing service for Phosphatidylethanol (PEth), a highly accurate biomarker of alcohol use, at Royal Prince Alfred Hospital. PEth testing is adopted into clinical practice as an eligibility criteria in transplant assessments, helping clinicians for the first time to make more informed decisions, adjust pre‑transplant care, and improve post‑transplant outcomes. This shift has delivered significant health and economic benefits. PEth test, now rebatable under MBS, is also incorporated in the management of AUD in addiction clinics.

Uncovering the first genetic link between lipid (fat) biology and cirrhosis risk Seth established a new field defining lipotoxicity as a central driver of chronic liver disease. To better understand how fatty liver disease progresses to cirrhosis, the team has created innovative preclinical and custom designed CRISPR‑Cas9 genetic models of alcohol- and diet-induced fatty liver in zebrafish. These models allow researchers to study how harmful fat builds up in the liver and damages cells. The Seth Lab is now exploring new ways to directly target and reduce this toxic fat using plasma‑polymerised nanoparticle delivery systems, a PhD program developed in collaboration with the University of Sydney’s Biomedical Engineering team.

  • Liver
  • Alcohol
  • Genetics
  • Genomics
  • Lipid biology

  • Liver diseases: Fatty liver, Liver cirrhosis and liver cancer, Alcohol-related liver disease (ALD), Metabolic dysfunction associated ALD (metALD)
  • Nanomedicine: lipid targeting delivery platform
  • Omics: genomics, transcriptomics, lipidomics, miRNAs, mass cytometry
  • Experimental models of liver diseases: zebrafish, mice, adult stem cell-derived hepatocyte like cells.

ALL PUBLICATIONS

People

Student opportunities

To learn more about student opportunities in the Seth Laboratory and for all general enquiries relating to our work, please contact Adjunct Professor Devanshi Seth.

Current opportunities:

Applying genetic risk algorithm to identify patients at high risk of chronic liver diseases

Primary Supervisor: Adjunct Professor Devanshi Seth
Supervisory Team: Adjunct Professor Devanshi Seth
Centre: Healthy Ageing
Project type: PhD

Liver cirrhosis is one of the most common life-threatening diseases. Alcohol misuse is the major cause of alcohol-related cirrhosis (ALC), followed by the metabolic dysfunction-associated steatotic liver disease (MASLD), affecting a quarter of global adults. ALC contributes to approximately half of all liver disease related mortality with a median survival post-hospital admission of 2.5 years, worse than that of many cancers. Both ALD and MASLD are preventable if detected early. But patients remain asymptomatic until advanced disease presentation, making it difficult for clinicians to predict who are at a greater risk of preventable cirrhosis and its complications, causing loss of productivity, illness, health care utilisation and death.

Genetic susceptibility to liver diseases is recent knowledge with evidence of shared genetic risks between ALC and MASLD. Our genomic studies in ALC recently developed genetic algorithms combining clinical risk (diabetes) that can predict a 10-fold increased cirrhosis risk in drinkers (PMC8803006) and a polygenic risk score (PRSALC) that also identifies high-risk MASLD patients (PMC11093576). This new knowledge allows us to identify people at the highest risk of progressive liver damage. However, genetic testing for liver diseases is not currently practiced leaving a gap in early identification and treatment of high-risk patients.

With my team of multidisciplinary clinicians, geneticist and genetic statisticians we aim to (i) investigate the prevalence of cirrhosis risk alleles in diverse populations using publicly available genetic databases (UK Biobank, Medical Genome Reference Bank) and (ii) test our algorithms for risk prediction as a follow-up in our existing GenomALC and UK Biobank cohorts of drinkers. Knowing the genetic risk prevalence in diverse populations and predictability of risk algorithms has high potential of developing and evaluating the best individualised value-add treatment for the two most prevalent liver diseases.

 

A novel nanoparticle platform targeting hepatic lipotoxicity to attenuate fatty liver diseases

Primary Supervisor: Adjunct Professor Devanshi Seth
Supervisory Team: Professor Marcela Bilek, Dr Bobby Boumelhem
Centre: Healthy Ageing
Project type: PhD

Build-up of liver lipid is the first hallmark of initiation of chronic liver diseases. There is compelling evidence that fatty liver, with persistent lipid excess induces lipotoxicity, a major risk for fibrosis, cirrhosis and cancer (PMC6888337). Current pharmacological treatments focused on targeting established liver diseases remain abysmal, limited by high costs and side effects. Fatty liver diseases are reaching epidemic proportions globally, current therapies are unlikely to benefit at population level underscoring an unmet need to invest in novel directions for preventive and cost-effective therapies. New knowledge from genome wide association studies (GWAS) show that most alleles associated with risk of cirrhosis reside in genes with functions in lipid droplet biology and/or lipid metabolism, strongly linking genetic susceptibility to lipotoxicity (PMID: 32853455, PMC8803006). Thus our novel strategies proposed in this project are to (i) develop dietary nutrients (such as L-carnitine, caffeine, paraxanthine, naringenin) as therapeutic agents targeting downstream dysregulated lipid pathways associated with risk variants, and (ii) develop Plasma Polymerised Nanoparticles (PPNs) as unique drug delivery platforms to target the root cause, i.e. excess lipid driven hepatic lipotoxicity. Our team collaborators have novel IP protected ‘histochemions’, PPNs linked to Nile Red (NR) a lipophilic dye that binds to neutral lipids such as triglycerides and cholesterol, that preferentially steer histochemions towards enriched TG and cholesterol, and Nile Blue (NB) that binds to fatty acids. We have preliminary data that these histochemions can simultaneously bind to multiple cargoes covalently, including dietary nutrients and hepatocyte homing molecules (albumin, indocyanin green, asialoglycoprotein receptor), allowing specific drugs to be linked for targeting lipids and lipid pathways in the liver. This project will advance these findings, optimise delivery and intervention protocols and test the functionality of modified PPN-based drug delivery platforms in vitro (cell culture) and in vivo in our customised pre-clinical CRISPR-Cas9 risk gene depletion models of fatty liver in zebrafish (PMID37650211). Use of nutrients are already in the disease management guidelines adjunct to other therapies, as early-stage therapeutic agents. The proposed dietary nutrients are known to reduce hepatic lipotoxic injury (inflammation, mitochondrial and oxidative stress) with zero-minimal toxicity, and are the choice of drugs in this project. Our multidisciplinary team expertise in nanotechnology, genetics, biomedical engineering, lipidomics, liver diseases and clinical hepatology, preliminary data, IP protected nanoparticle platform, pre-clinical models, established protocols, core facilities (zebrafish husbandry, flow cytometry, confocal imaging) and conducive work environment, we are best placed for the successful completion of this project. This project is highly likely to generate new IP/patents and has the potential to open up avenues for exploring cost-effective therapies targeting early stages of fatty liver to prevent disease progression. Techniques: Nanotechnology, lipidomics, zebrafish husbandry, flow cytometry, confocal imaging, molecular biology, CRISPR-Cas9. Funding is being sourced through grant applications in review/to be submitted.